Background: Mediterranean and vegan diets improve body weight and gut microbiome composition. The aim of this study was to compare both diets head-to-head.

Methods: Randomized cross-over trial, conducted February-October 2019. Sixty-two overweight adults were assigned to each diet for 16-week periods in random order, separated by a 4-week washout. Body weight was the primary outcome. Secondary measures included changes in gut microbiome which was measured using 16S rRNA sequencing.

Results: Body weight decreased on the vegan compared with the Mediterranean diet (treatment effect -6.0 kg [95% CI -7.5 to -4.5]; p<0.001). The relative abundance of Bacteriodetes decreased (p<0.001 for both diets) and Eubacteria increased on both diets (p<0.001 for the Mediterranean and p=0.009 for the vegan diet). The relative abundance of Lachnospiraceae increased (p=0.03), the Firmicutes to Bacteroidetes ratio increased (p=0.04) and the butyrate-producing bacteria decreased (p=0.02) on the Mediterranean diet. The relative abundance of Proteobacteria decreased (p<0.001), and Enterobacteria and Ruminococcus increased on the vegan diet (p=0.04 and p<0.001, respectively). Changes in body weight correlated positively with changes in relative abundance of Firmicutes both on the Mediterranean (r=+0.36; p=0.01) and the vegan diet (r=+0.41; p<0.001) and with changes in relative abundance of Lachnospiraceae both on the Mediterranean (r=+0.40; p<0.001) and the vegan diet (r=+0.44; p<0.001). In addition, the changes in body weight correlated negatively with changes in relative abundance of Enterobacteria on the Mediterranean diet (r=-0.32; p=0.02) and Eubacteria on the vegan diet (r=-0.49; p<0.001).

Conclusions: A low-fat vegan diet lead to a greater weight loss compared with a Mediterranean diet. This may be partly explained by the difference in gut microbiome composition.

Disclosure

H. Kahleova: None. R. Holubkov: Advisory Panel; Self; National Institutes of Health, U. S. Food and Drug Administration, Board Member; Self; Pfizer Inc., Revance Therapeutics. N. Barnard: None.

Funding

Physicians Committee for Responsible Medicine

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.